Cannabinoids Reduced Itching but Not Other Skin Symptoms in Meta-Analysis

Cannabinoid treatment significantly reduced pruritus (SMD=-0.29, 95% CI: -0.52 to -0.06, I-squared=0%). No significant effects were found for skin dryness (SMD=-0.22), erythema (SMD=-0.33, borderline), quality of life (SMD=-0.15), atopic dermatitis composite scores (SMD=-0.19), or transepidermal water loss (SMD=0.16).

Systematic review and meta-analysis searching PubMed, Embase, Scopus, Web of Science, and CENTRAL through June 2024. Included 11 RCTs, 3 quasi-experimental, and 3 observational studies (3,359 participants). Standard mean differences with 95% CIs. Risk of bias assessed with RoB 2 and ROBINS-I. PROSPERO: CRD42023397189.

Cannabis-based skincare products are a growing market, often marketed with broad claims about skin health. This is the first meta-analysis to quantitatively assess these claims, finding that only itch relief has statistical support while other dermatologic benefits remain unproven.

The itching result, while modest, is notable because pruritus is a common and difficult-to-treat symptom across many skin conditions. The zero heterogeneity (I-squared=0%) for this outcome is reassuring. However, the lack of benefit for other skin outcomes means cannabinoid skincare claims should be viewed with skepticism.

Included studies varied in cannabinoid formulations (CBD, PEA, cannabis extract, HU-210, alkylamides). Short follow-up periods in most studies. Publication bias possible. Small to moderate effect sizes. Topical formulations may not reflect systemic cannabinoid therapy effects.